21 Heard J M, Herbomel P, Ott M O, et al. Determinants of rat albumin promoter tissue specificity analyzed by an improved transient expression system. Mol Cell Biol, 1987, 7: 2425-2434
[2]
22 Kraus C L, Culican S M. Nummular keratopathy in a patient with Hyper-IgD Syndrome. Pediatr Rheumatol Online J, 2009, 7: 14？？
[3]
23 Sornsakrin M, Wenner K, Ganschow R B. cell cytopenia in two brothers with hyper-IgD and periodic fever syndrome. Eur J Pediatr, 2009,168: 825-831？？
[4]
24 Attout H, Guez S, Ranaivo I, et al. A patient with hyper-IgD syndrome responding to simvastatin treatment. Eur J Intern Med, 2008, 19: e82-83？？
[5]
25 Coban E, Terzioglu E A. patient with hyper-IgD syndrome in Antalya, Turkey. Clin Rheumatol, 2004, 23: 177-178？？
[6]
26 Tronche F, Rollier A, Bach I, et al. The rat albumin promoter: cooperation with upstream elements is required when binding of APF/HNF1 to the proximal element is partially impaired by mutation or bacterial methylation. Mol Cell Biol, 1989, 9: 4759-4766
[7]
27 Zhang D E, Ge X, Rabek J P, et al. Functional analysis of the trans-acting factor binding sites of the mouse alpha-fetoprotein proximal promoter by site-directed mutagenesis. J biol chem, 1991, 266: 21179-21185
[8]
28 Izban M G, Papaconstantinou J. Cell-Specific expression of mouse albumin promoter-evidence for cell-specific DNA elements within the proximal promoter region and cis-acting DNA elements upstream of-160. J biol chem, 1989, 264: 9171-9179
[9]
29 Pinkert C A, Ornitz D M, Brinster R L, et al. An albumin enhancer located 10-kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Gene Dev, 1987, 1: 268-276？？
[10]
30 Hu J M, Camper S A, Tilghman S M, et al. Functional analyses of albumin expression in a series of hepatocyte cell lines and in primary hepatocytes. Cell Growth Differ, 1992, 3: 577-588
[11]
31 Clark A J, Cowper A, Wallace R, et al. Rescuing transgene expression by co-integration. Biotechnology (NY), 1992, 10: 1450-1454？？
[12]
32 Tang B, Yu S, Zheng M, et al. High level expression of a functional human/mouse chimeric anti-CD20 monoclonal antibody in milk of transgenic mice. Transgenic Res, 2008, 17: 727-732？？
[13]
33 Enjuanes L, Sola I, Castilla J, et al. Transgenic mice secreting coronavirus neutralizing antibodies into the milk. J Virol, 1998, 72:3762-3772
[14]
34 Fine J M, Rivat C, Lambin P, et al. Monoclonal IgD. A comparative study of 60 sera with IgD “M” component. Biomedicine, 1974, 21:119-125
[15]
35 Fibbe W E, Jansen J. Prognostic factors in IgD myeloma: a study of 21 cases. Scand J Haematol, 1984, 33: 471-475
[16]
36 Rowe D S, Hug K, Forni L, et al. Immunoglobulin-D as a Lymphocyte Receptor. J Exp Med, 1973, 138: 965-972？？
[17]
37 Ligthart G J, Schuit H R, Hijmans W. Subpopulations of mononuclear cells in ageing: expansion of the null cell compartment and decrease in the number of T and B cells in human blood. Immunology, 1985, 55: 15-21
[18]
38 Chen K, Xu W, Wilson M, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol, 2009, 10: 889-898？？
[19]
39 Obici L, Manno C, Muda A O, et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum, 2004, 50: 2966-2969？？
[20]
1 Drenth J P, Prieur A M. Occurrence of arthritis in hyperimmunoglobulinaemia D. Ann Rheum Dis, 1993, 52: 765-766
[21]
2 Drenth J P, Boom B W, Toonstra J, et al. Cutaneous manifestations and histologic findings in the hyperimmunoglobulinemia D syndrome. International Hyper IgD Study Group. Arch Dermatol, 1994, 130: 59-65？？
[22]
3 Drenth J P, Haagsma C J, van der Meer J W. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore), 1994, 73: 133-144
[23]
4 Klasen I S, Goertz J H, van de Wiel G A, et al. Hyper-immunoglobulin A in the hyperimmunoglobulinemia D syndrome. Clin Diagn Lab Immun, 2001, 8: 58-61
[24]
5 Frenkel J, Rijkers G T, Mandey S H, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum, 2002, 46: 2794-2803？？
[25]
6 van der Meer J W, Vossen J M, Radl J, et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet, 1984, 1:1087-1090
[26]
7 Drenth J P, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet, 1999, 22: 178-181？？
[27]
8 Simon A, Cuisset L, Vincent M F, et al. Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-igd and periodic fever syndrome: its application as a diagnostic tool. Ann int med, 2001, 135: 338-343
[28]
9 Houten S M, van Woerden C S, Wijburg F A, et al. Carrier frequency of the V377I (1129G>A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet, 2003, 11: 196-200？？
[29]
10 Aringer M. Periodic fever syndromes-a clinical overview. Acta Med Austriaca, 2004, 31: 8-12
[30]
11 Drenth J P, van der Meer J W. Hereditary periodic fever. New Eng j mede, 2001, 345: 1748-1757？？
[31]
12 Hager E J, Tse H M, Piganelli J D, et al. Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome. J Inherit Metab Dis, 2007, 30: 888-895？？
[32]
13 Ammouri W, Cuisset L, Rouaghe S, et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology, 2007, 46: 1597-1600？？
[33]
14 Dikeacou T C, van Joost T, Cormane R H. The recruitment of inflammatory cells using the skin-window technique. Arch Dermatol Res,1979, 265: 1-7？？
[34]
15 Chen K and Cerutti A New insights into the enigma of immunoglobulin D. Immunol Rev, 2010, 237: 160-179？？
[35]
16 Vladutiu A O. Immunoglobulin D: properties, measurement, and clinical relevance. Clin Diagn Lab Immun, 2000, 7: 131-140
[36]
17 Naruto T, Nakagishi Y, Mori M, et al. Hyper-IgD syndrome with novel mutation in a Japanese girl. Mod Rheumatol, 2009, 19: 96-99？？
[37]
18 Yoshimura K, Wakiguchi H. Hyperimmunoglobulinemia D syndrome successfully treated with a corticosteroid. Pediatr Int, 2002, 44:326-327？？
[38]
19 Gorski K, Carneiro M, and Schibler U Tissue-specific in vitro transcription from the mouse albumin promoter. Cell, 1986, 47: 767-776
[39]
20 Herbomel P, Rollier A, Tronche F, et al. The rat albumin promoter is composed of six distinct positive elements within 130 nucleotides. Mol Cell Biol, 1989, 9: 4750-4758
